Author

Richard D. Lin

Vividion Therapeutics (United States)ORCID 0000-0002-2118-2590Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Aaron Nathan SneadiD· 1 shared Antonio Esparza-OrosiD· 1 shared Benjamin D. HorningiD· 1 shared Brian N. CookiD· 1 shared Chanyu Yue· 1 shared Cynthia BerryiD· 1 shared David S. WeinsteiniD· 1 shared Eileen TraniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron Nathan SneadORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologySciencePeer-reviewedOct 9, 2025

Covalent inhibitors of the RAS binding domain of PI3Ka impair tumor growth driven by RAS and HER2

Joseph E. Klebba, Nilotpal Roy, Steffen M. Bernard…·Matthew P. Patricelli

The paper develops covalent inhibitors targeting the RAS binding domain of PI3Kα, showing efficacy against RAS and HER2-driven tumors without affecting glucose homeostasis.

16 citationstop 4%

mouseexperimental assay